ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bayer will transfer most of its Berlin-based small-molecule drug research to Nuvisan, a German research services firm with expertise in clinical studies, lab services, and contract manufacturing. Nuvisan will take over a center on Bayer’s Berlin campus that employs about 400 researchers focused on activities including lead discovery, medicinal chemistry, and drug metabolism studies. Sanofi entered a similar partnership in 2015 when it transferred its small-molecule site in Toulouse, France, to the services firm Evotec.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter